On July 8, 2026, Calidi Biotherapeutics Inc. revealed that Sandra Gurrola has been appointed as VP Finance, Controller. To mark this occasion, the Compensation Committee and the Board of Directors sanctioned an inducement non-qualified stock option for her. This option allows her to purchase 100,000 shares at an exercise price of $0.15 each. The closing price of the Company’s common stock on July 6, 2026, the date of the grant, was $0.15. This move signifies Calidi’s commitment to boosting its leadership team and driving advancements in targeted genetic medicine.